Suppr超能文献

囊性纤维化腹部追踪器:一种针对囊性纤维化患者报告的每日胃肠道症状负担的特定结局指标。

CF Tummy Tracker: A Cystic Fibrosis-Specific Patient-Reported Outcome Measure for Daily Gastrointestinal Symptom Burden.

作者信息

Calthorpe Rebecca J, Saumtally Hisham A, Howells Laura M, Goodchild Natalie J, Evans Bethinn C, Elliott Zoe, Hayee Bu'Hussain, Carr Siobhán B, Elston Caroline M, Horsley Alexander A R, Peckham Daniel G, Barr Helen L, Major Giles A D, Stewart Iain D, Thomas Kim S, Smyth Alan R

机构信息

School of Medicine and NIHR Nottingham Biomedical Research Centre, Nottingham, United Kingdom.

Leeds Institute of Medical Research, University of Leeds, United Kingdom.

出版信息

Mayo Clin Proc Digit Health. 2025 Mar 3;3(2):100203. doi: 10.1016/j.mcpdig.2025.100203. eCollection 2025 Jun.

Abstract

OBJECTIVE

To develop a cystic fibrosis (CF)-specific patient-reported outcome measure (PROM) to measure the daily burden of gastrointestinal symptoms for people with cystic fibrosis (pwCF) aged 12 years and older and address the lack of validated outcome measures for gastrointestinal symptoms in CF.

PATIENTS AND METHODS

CF Tummy Tracker was developed through a 5-stage approach in accordance with regulatory guidance. This included development and refinement of a conceptual framework; item generation; refinement; reduction; selection; and initial PROM testing. A mixed-methods approach, consisting of expert panel discussions, a focus group, interviews, and an online survey, was used. In initial testing, participants completed the PROM daily for 14 days via a smartphone application. This study was performed from March 14, 2022, December 12, 2023.

RESULTS

The CF community were involved throughout the development via a focus group (n=7 pwCF), interviews (n=11 pwCF), and an online survey (n=180 pwCF). A formative model was confirmed for the PROM. The final PROM, CF Tummy Tracker, consists of 10 items capturing gastrointestinal symptom burden, tested in 151 pwCF. The PROM reported no floor or ceiling effects, high test-retest reliability (intra-class correlation coefficient=0.94), and strong correlation with the anchor question.

CONCLUSION

CF Tummy Tracker aims to address the gap in validated CF-specific PROMs for daily completion. Further testing of the psychometric properties of the PROM are planned in a new patient cohort to validate its use in clinical trials and support its use in both electronic and paper formats to increase accessibility.

摘要

目的

开发一种针对囊性纤维化(CF)的患者报告结局测量工具(PROM),以测量12岁及以上囊性纤维化患者(pwCF)胃肠道症状的日常负担,并解决CF中缺乏经过验证的胃肠道症状结局测量工具的问题。

患者与方法

CF腹部追踪器根据监管指南通过五阶段方法开发。这包括概念框架的开发和完善;条目生成;完善;缩减;选择;以及PROM初始测试。采用了混合方法,包括专家小组讨论、焦点小组、访谈和在线调查。在初始测试中,参与者通过智能手机应用程序连续14天每天完成该PROM。本研究于2022年3月14日至2023年12月12日进行。

结果

CF群体通过焦点小组(n = 7名pwCF)、访谈(n = 11名pwCF)和在线调查(n = 180名pwCF)全程参与开发。为该PROM确认了一个形成性模型。最终的PROM,即CF腹部追踪器,由10个捕捉胃肠道症状负担的条目组成,在151名pwCF中进行了测试。该PROM没有地板效应或天花板效应,重测信度高(组内相关系数 = 0.94),并且与锚定问题有很强的相关性。

结论

CF腹部追踪器旨在填补经过验证的特定于CF的每日完成的PROM的空白。计划在新的患者队列中对该PROM的心理测量特性进行进一步测试,以验证其在临床试验中的应用,并支持其以电子和纸质格式使用,以提高可及性。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/3801/12191005/ab37db68bbe8/gr1.jpg

相似文献

1
CF Tummy Tracker: A Cystic Fibrosis-Specific Patient-Reported Outcome Measure for Daily Gastrointestinal Symptom Burden.
Mayo Clin Proc Digit Health. 2025 Mar 3;3(2):100203. doi: 10.1016/j.mcpdig.2025.100203. eCollection 2025 Jun.
2
3
Inhaled mannitol for cystic fibrosis.
Cochrane Database Syst Rev. 2018 Feb 9;2(2):CD008649. doi: 10.1002/14651858.CD008649.pub3.
4
Interventions for preventing distal intestinal obstruction syndrome (DIOS) in cystic fibrosis.
Cochrane Database Syst Rev. 2018 Jun 12;6(6):CD012619. doi: 10.1002/14651858.CD012619.pub2.
5
Interventions for preventing distal intestinal obstruction syndrome (DIOS) in cystic fibrosis.
Cochrane Database Syst Rev. 2021 Dec 22;12(12):CD012619. doi: 10.1002/14651858.CD012619.pub3.
6
Exercise versus airway clearance techniques for people with cystic fibrosis.
Cochrane Database Syst Rev. 2022 Jun 22;6(6):CD013285. doi: 10.1002/14651858.CD013285.pub2.
7
Airway clearance techniques compared to no airway clearance techniques for cystic fibrosis.
Cochrane Database Syst Rev. 2023 Apr 12;4(4):CD001401. doi: 10.1002/14651858.CD001401.pub4.
8
Ataluren and similar compounds (specific therapies for premature termination codon class I mutations) for cystic fibrosis.
Cochrane Database Syst Rev. 2023 Mar 3;3(3):CD012040. doi: 10.1002/14651858.CD012040.pub3.
9
Interventions for improving adherence to airway clearance treatment and exercise in people with cystic fibrosis.
Cochrane Database Syst Rev. 2023 Jul 18;7(7):CD013610. doi: 10.1002/14651858.CD013610.pub2.
10
Nebulised hypertonic saline for cystic fibrosis.
Cochrane Database Syst Rev. 2018 Sep 27;9(9):CD001506. doi: 10.1002/14651858.CD001506.pub4.

本文引用的文献

2
A grumbling concern: A survey of gastrointestinal symptoms in cystic fibrosis in the modulator era.
NIHR Open Res. 2024 Feb 5;3:18. doi: 10.3310/nihropenres.13384.1. eCollection 2023.
3
Thinking outside the box: a review of gastrointestinal symptoms and complications in cystic fibrosis.
Expert Rev Respir Med. 2023 Jul-Dec;17(7):547-561. doi: 10.1080/17476348.2023.2228194. Epub 2023 Jun 26.
4
A refresh of the top 10 research priorities in cystic fibrosis.
Thorax. 2023 Aug;78(8):840-843. doi: 10.1136/thorax-2023-220100. Epub 2023 Jun 7.
5
Elexacaftor/tezacaftor/ivacaftor and gastrointestinal outcomes in cystic fibrosis: Report of promise-GI.
J Cyst Fibros. 2023 Mar;22(2):282-289. doi: 10.1016/j.jcf.2022.10.003. Epub 2022 Oct 21.
7
Telehealth after the pandemic: Will the inverse care law apply? (Commentary).
J Cyst Fibros. 2021 Dec;20 Suppl 3:47-48. doi: 10.1016/j.jcf.2021.08.023. Epub 2021 Sep 11.
8
Utilization of electronic patient-reported outcome measures in cystic fibrosis research: Application to the GALAXY study.
J Cyst Fibros. 2021 Jul;20(4):605-611. doi: 10.1016/j.jcf.2021.07.002. Epub 2021 Jul 22.
9

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验